5 minOn June 4, 2026, Innovent Biologics, Inc. announced that its innovative Claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC), IBI343 (arcotatug tavatecan), has successfully met the primary endpoint of progression-free survival (PFS) in the G-HOPE-001 study, an international multicenter Phase 3 clinical trial for advanced gastric cancer, following the per-protocol first interim analysis.
Based on these groundbreaking clinical results, the China National Medical Products Administration (NMPA) has formally accepted the New Drug Application (NDA) for IBI343 and granted it Priority Review status. This milestone marks the first time a CLDN18.2-targeted ADC has been submitted for regulatory review globally, offering a promising new standard of precision therapy for patients with advanced gastric cancer.
Addressing the Critical Unmet Need in Gastric Cancer
Gastric cancer remains one of the most prevalent and lethal malignancies worldwide, with metastatic patients facing a 5-year survival rate of less than 5%. After failing first- and second-line systemic therapies, patients often face rapid disease progression and a severe lack of effective subsequent treatment options.
Currently, the median survival for patients in the third-line setting and beyond is typically only about six months. In this context, identifying novel, high-efficacy targets is essential for improving prognosis. CLDN18.2, a tight-junction protein highly expressed in approximately 80% of gastric cancer cases, has emerged as a "star target" for precision oncology.
Innovative Mechanism: How IBI343 Delivers "Precision Killing"
IBI343’s success in its Phase 3 trial is attributed to its sophisticated molecular design. As a biomarker-driven ADC, it consists of a high-affinity anti-CLDN18.2 antibody, a potent topoisomerase I inhibitor (TOPO1i) payload, and a cleavable linker.
-
Precision Targeting and Degradation: IBI343 binds specifically to CLDN18.2 on the surface of tumor cells, triggering receptor-mediated internalization. Once inside, the cytotoxic payload is released, causing DNA damage and inducing apoptosis.
-
Bystander Killing Effect: The released payload can penetrate plasma membranes to eliminate neighboring tumor cells, even those with lower target expression.
-
Safety Optimization: By incorporating Fc-silencing technology, IBI343 minimizes off-tumor toxicity, achieving a superior balance between high potency and manageable safety.
International Validation: Clinical Significance of G-HOPE-001
The G-HOPE-001 study is an international, randomized, open-label Phase 3 trial conducted concurrently in China and Japan. It aims to directly compare IBI343 monotherapy against investigator-selected therapy in patients with CLDN18.2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who have received at least two prior systemic therapies.
"The success of IBI343 in this pivotal Phase 3 study marks a significant step forward for precision oncology in gastrointestinal cancers," said Professor Lin Shen, Director of the Department of Gastrointestinal Oncology at Beijing Cancer Hospital. "Its excellent efficacy and manageable safety profile offer a potential new standardized treatment option to improve the precision management of GI tumors."
Professor Kohei Shitara, Director of the Department of Gastrointestinal Oncology at the National Cancer Center Hospital East in Japan, added: "IBI343 has demonstrated good tolerability with low gastrointestinal toxicity. In patients with high CLDN18.2 expression, it shows encouraging anti-tumor potential, laying a solid foundation for its clinical application."
Strategic Vision: Innovent’s ADC Pipeline
The success of IBI343 reinforces Innovent's strategic leadership in the ADC space. Beyond the currently submitted indication for gastric cancer, IBI343 is undergoing robust development across other solid tumors, including a Phase 3 trial for CLDN18.2-positive advanced pancreatic cancer and ongoing Phase 1 trials exploring first-line settings.
In October 2025, Innovent entered into a global strategic partnership with Takeda Pharmaceuticals, granting Takeda exclusive rights to IBI343 outside of Greater China, highlighting the drug's global therapeutic potential.
With the NDA under priority review, IBI343 is on the cusp of market entry. For advanced gastric cancer patients who have exhausted traditional chemotherapy and immunotherapy, this first-in-class CLDN18.2 ADC represents a potential breakthrough in restoring hope. Detailed data from the G-HOPE-001 study is expected to be presented at upcoming international academic conferences.
